Factors affecting health related quality of life of patients with inflammatory bowel disease
Cite this article as: Casellas, F., López-Vivancos, J., Casado, A. et al. Qual Life Res (2002) 11: 775. doi:10.1023/A:1020841601110 Abstract
Using a disease specific instrument to measure the health related quality of life (HRQOL) of patients with inflammatory bowel disease (IBD), it has been shown that their perceived HRQOL worsens during active disease. The precise factors involved in HRQOL changes reported by these patients are largely unknown. Our aim was to elucidate which socio-demographic and health status variables are related with HRQOL in IBD patients. To this end, 354 patients with IBD were interviewed. To quantify the impairment in the HRQOL, the 36-item version of the inflammatory bowel disease questionnaire (IBDQ) was administered to all patients. To explore the relation of each individual variable on the HRQOL an univariate analysis by using the Spearman correlation, the Mann–Whitney or the Kruskal–Wallis test was performed when necessary. Factors significant at the univariate analysis were assessed using multiple linear regression modeling with global IBDQ score as the dependent factor.
Results: Disease type did not predict IBDQ score in the univariate nor in the multivariate analysis. Consequently, statistical analysis was performed in the global group of 354 patients independently of the type of disease. Lower recurrence/year index, longer disease duration, higher level of education, symptom activity, male gender and non-necessity of hospitalization all predict a better HRQOL ( p < 0.05). Factors which remained significant ( p < 0.05) in the multiple regression modeling were gender, need of hospitalization, symptomatic activity, recurrence/year index and education level. Conclusions: Symptomatic activity and socio-demographic variables such as gender and education are the most important factors involved in the impairment of HRQOL in patients with IBD. Crohn's disease Health care Health related quality of life Inflammatory bowel disease Ulcerative colitis References
Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998; 115: 182–205.
Ghosh S, Shand A, Ferguson A. Ulcerative colitis. Br Med J 2000; 320: 1119–1123.
Mitchell A, Guyatt G, Singer J, Irvine EJ. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988; 10: 306–310.
Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804–810.
Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI. Health related quality of life in inflammatory bowel disease: Functional status and patient worries and concerns. Dig Dis Sci 1989; 34: 1379–1386.
Farmer RG, Easley KA, Farmer JM. Quality of life assessment by patients with inflammatory bowel disease. Cleve Clin J Med 1992; 59: 35–42.
Badia X, Fernández E, Segura A. Influence of socio-demographic and health status variables on evaluation of health states in a Spanish population. Eur J Publ Heath 1995; 5: 87–93.
Sackett DL, Torrance DW. The utility of different health states as perceived by the general public. J Chron Dis 1978; 7: 347–358.
Froberg DG, Kane RL. Methodology for measuring health-state preferences: Population and context effects. J Clin Epidemiol 1989; 42: 585–592.
Casellas F, López-Vivancos J, Badía X, Vilaseca J, Malagelada J-R. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001; 13: 567–572.
Irvine EJ, Grace E, Kerr GD, et al. Non-disease related factors affectinghealth related quality of life in inflammatory bowel disease. Gastroenterology 1998; 114: A1002.
Casellas F, López-Vivancos J, Badia X, Vilaseca J, Malagelada J-R. Impact of surgery for Crohn's disease on health related quality of life. Am J Gastroenterol 2000; 95: 177–182.
Cuntz U, Welt J, Rupert E, Zillessen E. Determination of subjective burden from chronic inflammatory bowel disease and its psychosocial consequences. Results from a study of 200 patients. Psychother Psychosom Med Psychol 1999; 49: 494–500.
Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1: 514.
Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized trial. Br Med J 1989; 298: 82–86.
López-Vivancos J, Casellas F, Badia X, Vilaseca J, Malagelada J-R. Validation of the Spanish version of the in-flammatory bowel disease questionnaire in ulcerative colitis and Crohn's disease. Digestion 1999; 60: 274–280.
Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992; 14: 15–19.
SoláR, García-Pugés A, Monés J, et al. Enfermedad inflamatoria crónica intestinal en Cataluña (Barcelona y Gerona). Rev Esp Enf Digest 1992; 81: 7–14.
Fraga X, Vergara M, Medina C, Casellas F, Bermejo B, Malagelada J-R. Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 683–687.
Casellas F, López-Vivancos J, Vergara M, Malagelada J-R. Impact of inflammatory bowel disease on health-related quality of life. Dig Dis 1999; 17: 208–218.
Casellas F, López-Vivancos J, Badia X, Vilaseca J, Malagelada J-R. Self perception of health and compliance of maintenance treatment in patients with ulcerative colitis. Gastroenterology 2000; 118: A1336.
De Boer A, Sprangers M, Bartelsman J, de Haes H. Predictors of health care utilization in patients with inflammatory bowel disease: A longitudinal study. Eur J Gastroenterol Hepatol 1998; 10: 783–789.
Moser G, Tillinger W, Sachs G, et al. Disease-related worries and concerns: A study on out-patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7: 853–858.
Kinash RG, Fischer DG, Lukie BE, Carr TL. Inflammatory bowel disease impact and patients characteristics. Gastroenterol Nurs 1993; 15: 147–155.
Hilsden RJ, Hodgins DC, Timmer A, Sutherland LR. Helpingpatients with Crohn's disease quit smoking. Am J Gastroenterol 2000; 95: 352–358.
Boyko EJ, Koepsell TD, Perera DR, Inui TR. Risk of ulcerative colitis amongformer and current cigarette smokers. N Engl J Med 1987; 316: 707–710.
Silverstein MD, Lashner BA, Hanauer SB, Evans AA, Kirsner JB. Cigarette smoking in Crohn's disesae. Am J Gastroenterol 1989; 84: 31–33.
Cottone M, Rosselli M, Orlando A, Oliva L, Poleo A, Cappello M. Smokinghabits and recurrence in Crohn's disease. Gastroenterology 1994; 106: 643–648.
Presson PG, Ahlbom A, Hellers G. Inflammatory bowel disease and tobacco smoke-a case control study. Gut 1990; 31: 1377–1381.
Russel MG, Nieman FH, Bergers JM, Stockbrügger RW. Cigarette smoking and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8: 1075–1081.
Anam S, Hanauer S. The effect of gender on quality of life instruments in inflammatory bowel disease. Gastroenterology 1998; 114: A919.
Irvine EJ, Greenberg GR, Feagan BG, et al. Quality of life improves with budesonide therapy for active Crohn's disease. Inflammatory Bowel Dis 2000; 6: 181–187.
Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut 2000; 47: 444–454.
Google Scholar Copyright information
© Kluwer Academic Publishers 2002